Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

Key Points

• To compare the effectiveness of dupilumab and tralokinumab in treating atopic dermatitis using real-world data.
• Conducted a real-world comparison study using propensity score adjustments.
• Analyzed effectiveness based on EASI and NRS-pruritus scores.
• Considered treatment discontinuation rates in assessments.
• Dupilumab demonstrated superior effectiveness compared to tralokinumab.
• Small differences in EASI and NRS-pruritus for ongoing respondents.
• More notable differences seen with specific treatment targets for EASI and pruritus.